In vitro studies have shown that combining MDM2 antagonists with Peg IFN-α 2a effectively targets hematopoietic progenitor cells in PV, significantly reducing the population of malignant progenitor cells (PV) [49]. Here, MDM2 is linked to acquired polycythemia vera.